8-K: Cycle Pharma to Acquire Applied Therapeutics for Cash, CVRs

Applied Therapeutics agrees to be acquired by Cycle Group Holdings for $0.088 per share in cash plus contingent value rights tied to drug development and sales milestones, alongside an $8.5 million unsecured loan.

Summary

• Cycle Group Holdings Limited will acquire Applied Therapeutics, Inc. through a tender offer and subsequent merger.
• Shareholders will receive $0.088 per share in cash and one non-tradeable Contingent Value Right (CVR) for each share.
• CVRs offer potential additional payments: $0.10 for FDA approval of govorestat for galactosemia, $0.10 for FDA approval for CMT-SORD, and $0.20 if worldwide net sales of any CVR product exceed $200 million in any four-quarter period.
• CVR holders are also entitled to a pro rata share of Applied's cash exceeding $500,000 at closing, capped at $1.5 million.
• Applied Therapeutics received an unsecured promissory note from Cycle Group for up to $8.5 million to fund working capital and general corporate purposes, bearing 24% annual interest.
• The Applied Board of Directors unanimously approved the transaction, deeming it advisable and fair to shareholders, following an extensive evaluation of strategic alternatives.
• The transaction is expected to close in the first quarter of 2026, subject to customary closing conditions, including a majority of outstanding shares being tendered.

Sentiment

Score: 2

Explanation: While an acquisition provides an exit, the terms, particularly the low cash price and the high-interest bridge loan, strongly suggest a distressed sale. The CVRs offer potential upside but are non-tradeable and highly contingent. The alternative was a wind-down, making this a survival outcome rather than a strong positive.

Positives

• Provides immediate cash consideration of $0.088 per share to shareholders.
• Offers potential upside through CVRs tied to regulatory approvals and commercial success of govorestat, up to an additional $0.40 per CVR plus a share of closing cash.
• Secures up to $8.5 million in unsecured debt financing from Cycle Group, crucial for Applied Therapeutics' continued operations, which otherwise faced a limited cash runway and potential wind-down.
• The transaction was unanimously approved by the Applied Board of Directors, indicating a belief that it is in the best interests of the company and its stockholders.
• The offer is not subject to a financing condition, reducing transaction uncertainty.

Negatives

• The upfront cash consideration of $0.088 per share is relatively low.
• CVRs are non-tradeable, limiting liquidity and immediate value realization for shareholders.
• Achievement of CVR milestones is uncertain and depends on future regulatory approvals and commercial success, which are not guaranteed.
• The promissory note carries a high interest rate of 24% per annum, indicating financial distress for Applied Therapeutics.
• The company explicitly states that "Absent funds provided by Cycle under the Promissory Note or from another source, Applied would be unable to continue to fund its activities for more than a limited number of days and Applied would anticipate proceeding to wind down operations," suggesting a distressed sale.
• Out-of-the-money stock options will be cancelled without consideration if not exercised prior to the Effective Time.

Risks

• Uncertainty regarding the timing of the closing of the proposed transaction.
• Risk that closing conditions may not be satisfied within the expected timeframe or at all.
• Uncertainties as to how many Applied Therapeutics stockholders will tender their shares in the offer.
• Possibility of competing offers being made.
• Risk of an event, change, or circumstance that could lead to the termination of the Merger Agreement, potentially requiring Applied Therapeutics to pay a termination fee.
• Outcome of any legal proceedings related to the Merger Agreement.
• Unanticipated difficulties or expenditures relating to the proposed transaction.
• Response of business partners to the announcement and potential difficulties in employee retention.
• The possibility that CVR milestone payments will never be achieved, or if achieved, the amount may be less than expected.
• Risk that any equityholder litigation in connection with the proposed transactions may result in significant costs of defense, indemnification and liability.
• Applied Therapeutics' ability to successfully demonstrate the efficacy and safety of its drug candidates and obtain regulatory approvals.
• Dependence on successful clinical development, regulatory approval, and commercialization of product candidates.
• Inherent uncertainties associated with developing new products or technologies and operating as a clinical-stage company.
• Obligations under the Promissory Note and the ability to satisfy them.
• The company's cash sufficiency and runway, with a stated risk of winding down operations without the Promissory Note funds.

Future Outlook

The transaction is expected to close in the first quarter of 2026. The future outlook for Applied Therapeutics' lead drug candidate, govorestat, will be under Cycle Group Holdings' direction, with potential contingent payments to former shareholders tied to FDA approvals for galactosemia and CMT-SORD indications, and achievement of $200 million in worldwide net sales. The company's ability to continue operations is contingent on the funding provided by the Promissory Note from Cycle Group.

Management Comments

• Les Funtleyder, Interim CEO and CFO of Applied: "We are confident that Cycle has the resources and capabilities to move govorestat forward towards the ultimate goal of bringing a life-changing treatment to the patients suffering from Classic Galactosemia, CMT-SORD and PMM2-CDG, who have always been at the center of everything we do at Applied. I want to thank the entire Applied team for their perseverance and commitment. We are also grateful to the investigators and patients who have contributed to the development of govorestat."

Industry Context

This acquisition highlights the ongoing consolidation and strategic realignments within the biopharmaceutical sector, particularly for clinical-stage companies focused on rare diseases. Larger entities like Cycle Pharmaceuticals, which specializes in rare genetic conditions, are acquiring smaller firms with promising drug candidates to expand their pipelines and market reach. The structure of the deal, including contingent value rights, is a common mechanism in biotech acquisitions to share future risks and rewards, especially when drug development milestones are still pending. The explicit mention of Applied Therapeutics' limited cash runway and potential wind-down without the Promissory Note suggests a challenging funding environment for smaller clinical-stage companies, making strategic acquisitions a vital exit strategy.

Comparison to Industry Standards

• The upfront cash consideration of $0.088 per share is very low, especially for a company with a lead drug candidate in clinical development. This suggests a distressed sale, likely below what would be considered standard for a clinical-stage biotech with promising assets in a healthier financial position.
• The inclusion of CVRs is a common mechanism in biotech acquisitions, allowing the acquirer to limit upfront cash outlay while providing potential upside to selling shareholders based on future drug performance. However, the non-tradeable nature of these CVRs is less favorable than tradeable CVRs, which offer liquidity.
• The 24% interest rate on the unsecured promissory note is exceptionally high, far exceeding typical corporate lending rates, even for high-risk ventures. This underscores the severe financial constraints Applied Therapeutics was facing, indicating a last-resort financing option.
• The explicit statement about the company's inability to fund operations for more than a limited number of days without the loan is a stark indicator of financial distress, which is not a standard operating condition for a publicly traded company, even a clinical-stage one. This situation is comparable to companies nearing bankruptcy or facing imminent delisting due to lack of funds.

Management Changes

Corporate Governance

Legal Proceedings

• The Company is to comply with all terms of the Stipulation of Settlement for 'In re Applied Therapeutics Securities Litigation, Case No. 1:24-cv-09715 dated November 4, 2025.'
• The Company will direct its insurers to pay the Cash Settlement Amount to the Escrow Account as required by the settlement.

Related Party Transactions

• The Unsecured Promissory Note, dated December 11, 2025, between Applied Therapeutics, Inc. (Company) and Cycle Group Holdings Limited (Parent/Lender), provides unsecured debt financing up to $8.5 million at 24% interest, serving as a critical funding source from the acquirer.

Stakeholder Impact

• Shareholders: Will receive $0.088 cash per share and CVRs, which offer potential future payments but are non-tradeable and subject to significant risk. Those with out-of-the-money options face cancellation without consideration. The alternative was a potential wind-down of operations.
• Employees/Officers/Directors: Existing employment agreements will be maintained. Directors and officers will resign, and new management from Purchaser will take over. Indemnification and D&O insurance will be maintained for former directors and officers.
• Customers/Patients: The lead drug candidate, govorestat, is expected to continue development under Cycle Group Holdings, potentially bringing "life-changing treatment" to patients with rare CNS metabolic diseases.
• Creditors: The Promissory Note from Cycle Group provides critical funding, preventing a potential wind-down that would have negatively impacted creditors. Existing indebtedness will be paid off at closing.

Next Steps

• Purchaser will commence a tender offer to acquire all outstanding shares of Applied Therapeutics.
• Applied Therapeutics will file a Solicitation/Recommendation Statement on Schedule 14D-9.
• The transaction is expected to close in the first quarter of 2026.
• If the tender offer closes, a second-step merger will acquire untendered shares.
• Parent will use commercially reasonable efforts to achieve CVR milestones (FDA approvals for galactosemia and CMT-SORD, and $200 million in worldwide net sales).
• Company to comply with Stipulation of Settlement for 'In re Applied Therapeutics Securities Litigation' and direct insurers to pay Cash Settlement Amount.
• Company to cooperate with Parent for delisting from Nasdaq and deregistration under the Exchange Act after Effective Time.

Key Dates

Recommendation

The filing indicates a distressed sale of Applied Therapeutics. The upfront cash consideration of $0.088 per share is extremely low, reflecting the company's precarious financial position, explicitly stating it would otherwise "wind down operations." While contingent value rights (CVRs) offer potential future upside, they are non-tradeable, illiquid, and highly speculative, dependent on uncertain future regulatory approvals and sales milestones. The 24% interest rate on the bridge loan further underscores the company's dire financial state. Given the low cash offer, the high risk associated with CVRs, and the underlying financial distress, investors should sell their shares to realize the immediate cash value and avoid the speculative nature of the CVRs and the company's past financial challenges.

Keywords

Applied Therapeutics, Cycle Group Holdings, Merger Agreement, Tender Offer, Acquisition, Contingent Value Rights, CVR, Govorestat, Galactosemia, CMT-SORD, PMM2-CDG, Biopharmaceutical, Rare Diseases, FDA Approval, Promissory Note, Clinical Stage, Drug Development, Corporate Governance, SEC Filing, APLT, Cycle Pharmaceuticals